
Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
Avasarala, JagannadhaVolume:
11
Langue:
english
Journal:
Drug Target Insights
DOI:
10.1177/1177392817737515
Date:
January, 2017
Fichier:
PDF, 591 KB
english, 2017